Adrian Rawcliffe
2018
In 2018, Adrian Rawcliffe earned a total compensation of $1.4M as Chief Financial Officer at Adaptimmune Therapeutics, a 8% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $174,807 |
|---|---|
| Option Awards | $730,791 |
| Salary | $457,011 |
| Other | $46,778 |
| Total | $1,409,387 |
Rawcliffe received $730.8K in option awards, accounting for 52% of the total pay in 2018.
Rawcliffe also received $174.8K in non-equity incentive plan, $457K in salary and $46.8K in other compensation.
Rankings
In 2018, Adrian Rawcliffe's compensation ranked 7,467th out of 14,244 executives tracked by ExecPay. In other words, Rawcliffe earned more than 47.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,467 out of 14,244 | 48th |
Division Manufacturing | 2,898 out of 5,765 | 50th |
Major group Chemicals And Allied Products | 1,088 out of 2,128 | 49th |
Industry group Drugs | 919 out of 1,817 | 49th |
Industry Biological Products, Except Diagnostic Substances | 169 out of 339 | 50th |
Pay ratio
| Adrian Rawcliffe's Pay | $1,409,387 |
|---|---|
| Median Employee's Pay | $137,800 |
| Pay Ratio | 10to 1 |
In 2018, the annual total compensation of Adrian Rawcliffe was $1,409,387.
The annual total compensation of the median employee at Adaptimmune Therapeutics was $137,800.
The ratio of Adrian Rawcliffe's pay to the pay of median employee was therefore 10 to one.
Source: SEC filing on March 15, 2019.
Rawcliffe's colleagues
We found four more compensation records of executives who worked with Adrian Rawcliffe at Adaptimmune Therapeutics in 2018.